NEUMOLOGÍA PEDIÁTRICA

C o n t e n i d o d i s p o n i b l e e n h t t p : / / www. n e umo l o g i a - p e d i a t r i c a . cl 497 Hemosiderosis Pulmonar Idiopática. Presentación de un caso y revisión de la Literatura Neumol Pediatr 2020; 15 (4): 491 - 497 tps://www.cff.org/2014_CFF_Annual_Data_Report_to_ the_Center_Directors.pdf/ (último acceso julio, 2020). 5. Hamosh A, Fitz S, Macek M, et al. Comparison of the cli- nical manifestations of cystic fibrosis in black and white patients. J Pediatr. 1998; 132(2):255–9. 6. Cutting G, Engelhardt, Zeitin, P. Genética y fisiopatología de la fibrosis quística. En: Wilmott, Robert, Kendig. Enfer- medades respiratorias en niños. 9na Ed. Elsevier; 2019. 757-768. 7. Parkins M. Incidence and Risk Factors for Pulmonary Exacerbation Treatment Failures in Patients With Cystic Fibrosis Chronically Infected With Pseudomonas aerugi- nosa. CHEST J. 2012;141(2):485. 8. Federación Española contra la Fibrosis Quística [Inter- net]. Epidemiología y patogénesis. En: Libro blanco de atención a la fibrosis quística. 1 ra Ed. Madrid: Minis- terio de Sanidad y Consumo.2002;12-16. Disponible en: http://fqcantabria.org/wp-content/uploads/2017/10/ libro-blanco.pdf (último acceso marzo, 2020). 9. Segal E, Grenoville M, Macri C, et al. Consenso de Fi- brosis Quística. Arch argentinos Pediatr. 1999; 97:188– 224. 10. Dodge J, Lewis P, Stanton M, et al. Cystic fibrosis mor- tality and survival in the UK: 1947–2003. Eur Respir J 2007 Mar;29(3):522-6. 11. Cerda L J, Valdivia C G, Guiraldes C E, Sánchez D I. Mortalidad por fibrosis quística en Chile (1997-2003). Rev Med Chil. 2008; 136(2):157–62. 12. McKone E, Emerson S, Edwards K, et al. Effect of genoty- pe on phenotype and mortality in cystic fibrosis: a retros- pective cohort study. Lancet. 2003; 361(9370):1671–6. 13. Quintana E, Ruiz M, Delgado I, Calero C, Soriano J, Lo- pez-Campos J. Mortality from cystic fibrosis in Europe: 1994-2010. Pediatr Pulmonol. 2016;51(2):133–42. 14. Sociedad Argentina de Pediatría [Internet]. Comités Na- cionales de Neumología, Nutrición, Gastroenterología e Infectología. Consenso Nacional de Fibrosis quística Ar- gentina. Arch Argent Pediatr 2008; (Supl) 106 (5): e01- 52. Disponible en: https://www.sap.org.ar/docs/profe- sionales/consensos/v106n5a12e.pdf 15. Sanders D, Emerson J, Ren C, et al. Early childhood risk factors for decreased FEV1 at age six to seven years in young children with cystic fibrosis. Ann Am Thorac Soc. 2015;12(8):1170–6. 16. McPhail G, Acton J, Fenchel M et al. Improvements in Lung Function Outcomes in children with Cistyc Fibro- sis are Associated with Better Nutrition, Fewer Chronic Pseudomonas aeruginosa Infections, and Dornasa Alfa Use. J Pediatr 2008 Dec;153(6):752-7 17. Jímenez B. Los tres pilares del tratamiento en fibrosis quística: antibioterapia, fisioterapia, nutrición [Internet]. Federación Española contra la fibrosis quística. Valencia, 2011. Disponible en: https://fqvalenciana.com/wp-con- tent/uploads/2014/11/Los-tres-pilares-del-tratamiento- en-FQ.pdf (último acceso junio 2020). 18. Miller M, Crapo R, Hankinson J, et al. Series ATS/ERS task force: standardization of lung function testing. Eur Respir J 2005; 26: 319–338. 19. World Health Organization (WHO). Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. WHO Technical Report Series 854. Geneva: World Health Organization, 1995. Disponible en: http://apps.who.int/bmi/index.jsp?introPage=intro_3. html (último acceso diciembre 2019). 20. Lee T, Brownlee K, Conway S, et al. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2003 Mar;2(1):29-34 21. Accurso F, Sontag M, Wagener J. Complications asso- ciated with symptomatic diagnosis in infants with cystic fibrosis. J Pediatr 2005 Sep;147(3 Suppl): S37-41. 22. Connor G, Quinton H, Kneeland T, et al. Median House- hold Income and Mortality Rate in Cystic Fibrosis. Pedia- trics 2003 Apr;111(4 Pt 1): e333-9. 23. Wilschanski M, Braegger C, Colombo C, et al. Highlights of the ESPEN-ESPGHAN-ECFS Guidelines on Nutrition Care for Infants and Children with Cystic Fibrosis. J Pe- diatr Gastroenterol Nutr. 2016 Dec;63(6):671-675. 24. Hayes D Jr, Tobias J, Mansour HM, et al. Pulmonary hypertension in cystic fibrosis with advanced lung disea- se. Am J Respir Crit Care Med. 2014 oct;190(8):898- 905. 25. Li D, Wang B, Wang H, et al. Prognostic significance of pulmonary hypertension in patients with cystic fibrosis: A systematic review and meta-analysis. Medicine (Baltimo- re). 2018 Feb;97(7): e9708. 26. Jordana H, Brandie D, Wagner D. Sagel J, Zemanick1 E. Pulmonary exacerbations and clinical outcomes in a longitudinal cohort of infants and preschool children with cystic fibrosis. BMC Pulmonary Medicine (2017) 17:1-8 27. Emerson J. Rosenfeld M. McNamara S, et al. Pseudo- monas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002; 34:91–10 28. Fauroux B, Hart N, Belfar S, et al. Burkholderia cepacia Is Associated with Pulmonary Hypertension and Increased Mortality among Cystic Fibrosis Patients. J Clin Micro- biol. 2004 Dec; 42(12): 5537–5541 29. Emerson J, Rosenfeld M, Mcnamara S, et al. Original Articles Pseudomonas Aeruginosa and Other Predictors of Mortality and Morbidity in Young Children with Cystic Fibrosis. Pediatr Pulmonol 2002 Aug;34(2):91-100. 30. Barrios W, Altamar H, Jiménez O, et al. Caracterización de los pacientes con Fibrosis Quística, en la Costa Cari- be Colombiana en el periodo comprendido entre 2005 y 2012. Rev. Med. Evidencia 2014; 3 (1): 29-34.